Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Christopher C Rowe, Kathryn A Ellis, Miroslava Rimajova, Pierrick Bourgeat, Kerryn E Pike, Gareth Jones, Jurgen Fripp, Henri Tochon-Danguy, Laurence Morandeau, Graeme O'Keefe, Roger Price, Parnesh Raniga, Peter Robins, Oscar Acosta, Nat Lenzo, Cassandra Szoeke, Olivier Salvado, Richard Head, Ralph Martins, Colin L Masters Show all
Neurobiology of Aging | ELSEVIER SCIENCE INC | Published : 2010
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, a participant of the worldwide Alzheimer's Disease Neuroimaging Initiative (ADNI), performed (11)C-Pittsburgh Compound B (PiB) scans in 177 healthy controls (HC), 57 mild cognitive impairment (MCI) subjects, and 53 mild Alzheimer's disease (AD) patients. High PiB binding was present in 33% of HC (49% in ApoE-epsilon4 carriers vs 21% in noncarriers) and increased with age, most strongly in epsilon4 carriers. 18% of HC aged 60-69 had high PiB binding rising to 65% in those over 80 years. Subjective memory complaint was only associated with elevated PiB binding in epsilon4 carriers. There was no correlation with cognition i..View full abstract
The study was supported by the Commonwealth Scientific Industrial Research Organization (CSIRO) P-Health Flagship Collaboration Fund through the Australian Imaging, Biomarkers and Lifestyle Flagship study of Ageing (Australian Imaging, Biomarkers and Lifestyle [AIBL]), the Austin Hospital Medical Research Foundation, Neurosciences, Victoria, and the University of Melbourne.